Proqr Therapeutics (PRQR): Congress and insider trades
Who in Congress and inside the company traded PRQR, when each filing appeared, and what buying after each one would have earned against the S&P 500.
Key Facts
- Proqr Therapeutics (PRQR) is a listed stock on NASDAQ.
- Insiders filed 4 open market buys worth $988K and 0 sells worth $0, the latest filed 2026-07-21 (21 July 2026).
- Data as of 2026-09-29 (29 September 2026).
Insider trades in PRQR
as of 2026-07-21| Filed | Insider | Type | Shares | Price | Value | 90 day vs S&P |
|---|---|---|---|---|---|---|
| 21 Jul 2026 | Filius Bart | buy | 150,000 | $1.72 | $258K | n/a |
| 13 Jul 2026 | de Boer Daniel Anton | buy | 150,000 | $1.74 | $261K | n/a |
| 8 Jul 2026 | de Boer Daniel Anton | buy | 150,000 | $1.59 | $239K | n/a |
| 30 Jun 2026 | Filius Bart | buy | 150,000 | $1.54 | $231K | n/a |
Nothing matches that search.
Related pages
Frequently asked questions
Who has bought PRQR?
0 Congress buys by 0 members and 4 insider buys are on file. The tables on this page list every one.
Did buying PRQR after a disclosure beat the market?
No disclosed buy of this stock has matured 90 days yet. A single stock is a small sample.
Sources: Congressional trades: STOCK Act disclosures, collected from CapitolTrades. Insider trades: SEC Form 4 filings, collected from Finviz. Prices: Yahoo Finance daily adjusted closes. Data as of 2026-09-29 (29 September 2026). About these sources.
Not investment advice. Past disclosed trades do not predict future returns. Disclosures are published late, so the trades shown are ones you could only have copied after the fact. Talk to a licensed adviser before you invest.